Nuvation Bio - Class A opened lower at $4.22, compared with its previous close of $4.29. In the last trading session, the stock traded between $4.03 and $4.22. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Nuvation Bio - Class A is now worth
$ 44.57
Resulting in a loss of
$ 55.43 (55.43%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.23 (-5.45%)
Day High
$4.22
Day Low
$4.03
Day Open
$4.22
Prev Close
$4.29
Volume
49,77,578
1W Return
-13.61%
1M Return
-17.19%
3M Return
-36.48%
6M Return
-14.79%
1Y Return
-18.55%
Fundamentals
Market Cap ($ Mn)
1,432
PE Ratio
-
PB Ratio
9.18
PEG Ratio
-
ROE
-54.20%
ROCE
-41.66%
EPS (TTM)
$-0.12
Investment Returns
1 Week
-13.61%
1 Month
-17.19%
3 Months
-36.48%
6 Months
-14.79%
9 Months
-29.09%
Financials
Quarterly
All values in $ Mn
4.8
Jun 25
13.1
Sep 25
41.9
Dec 25
83.2
Mar 26
31.7
Jun 26
45.0
Sep 26
Updates
6Nov
RBC Capital lowers Nuvation Bio price target to $17
RBC Capital maintains Outperform rating on Nuvation Bio. Price target lowered from $20 to $17. Analyst Leonid Timashev issued the revised recommendation.
7 days ago
5Nov
Nuvation Bio Q3FY26 Results: Revenue $45M, Ibtrosi sales up 18% QoQ
Total revenue reached $45 million in Q3FY26, with Ibtrosi contributing $27.5 million. Ibtrosi net U.S. product revenue grew 18% sequentially despite a 15% drop in ROS1 market new patient starts. Safusidenib received FDA Fast Track designation for IDH1-mutant glioma with 52% ORR in Phase 2. Cash position stands at $663.4 million as of September 30, 2026. Ibtrosi holds over 60% market share in first-line new patient starts.
8 days ago
17Sep
Nuvation Bio stock rises 6% as FDA approves IBTROZI label update
Nuvation Bio stock rose 6.06% to $6.130 on Thursday. FDA approved IBTROZI sNDA four months ahead of PDUFA date. Label updated to show 49.7-month median duration of response. Safety profile remains unchanged with no new signals identified. EMA and UK MHRA validated MAAs in March and June 2026.
1mo ago
16Sep
Citizens maintains $10 target, Market Outperform on Nuvation Bio
Citizens analyst Silvan Turkcan reiterates Market Outperform rating. Price target for Nuvation Bio (NYSE:NUVB) remains at $10. No change in valuation outlook from previous assessment.
1mo ago
20Aug
FDA grants fast track designation to Nuvation Bio's safusidenib
Nuvation Bio received FDA Fast Track Designation for safusidenib, an oral inhibitor for IDH1-mutant glioma. The designation facilitates expedited review pending positive clinical data. Enrollment for the pivotal Phase 3 SIGMA study is currently in progress.
2mo ago
6Aug
Nuvation Bio Q2 Results: Sales surge 556% YoY to $31.7M
Nuvation Bio's Q2 results show a dramatic 555.64% YoY sales increase to $31.687M, beating estimates. EPS of $(0.18) beat the $(0.19) estimate but widened slightly from $(0.17) last year.
